跳到正文
原文
MedPage Today·· 9 天前精选AI 评分75

口服 GLP-1 受体激动剂或forglipron在中重度阻塞性睡眠呼吸暂停患者中的疗效

GLP-1 Pill Shows Benefit in Sleep Apnea

AI 导读

两项 III 期临床试验显示,口服 GLP-1 受体激动剂或forglipron显著改善了中重度阻塞性睡眠呼吸暂停患者的睡眠呼吸障碍。该药物还显示出对体重、炎症标志物和血压的有益影响。研究者认为这可能成为肥胖或超重成人中重度 OSA 的一种有前景的口服治疗选择。

推荐理由

两项 III 期临床试验显示口服 GLP-1 受体激动剂或forglipron显著改善中重度阻塞性睡眠呼吸暂停患者的睡眠呼吸障碍。

正文 · 原文

— If approved, orforglipron could become the first oral treatment for obstructive sleep apnea

by Susan Jeffrey, Contributing Writer, MedPage Today

November 10, 2026 • 3 min read

The oral GLP-1 receptor agonist orforglipron (Foundayo) improved sleep-disordered breathing in patients with moderate-to-severe obstructive sleep apnea and overweight or obesity, two phase III trials showed.

For the treatment regimen estimand, mean change of apnea-hypopnea index (AHI) was significantly improved from baseline to week 52 with orforglipron compared with placebo both in patients receiving continuous positive airway pressure (PAP; -17.3 vs -5.3 events/hour, P<0.001) and in patients not receiving PAP (-17.8 vs -4.5 events/hour, P<0.001).

Orforglipron also showed significant improvements in secondary outcomes, including the sleep apnea-specific hypoxic burden, as well as reductions in body weight, high-sensitivity C-reactive protein, and blood pressure, reported Vaishnavi Kundel, MD, of the Icahn School of Medicine at Mount Sinai in New York City.

"These data support the potential use of orforglipron as a promising oral treatment option for moderate-to-severe OSA [obstructive sleep apnea] in adults with obesity or overweight," Kundel said at the American Heart Association (AHA) annual meeting held in Chicago.

AHA commenter Michael Grandner, PhD, from the University of Arizona in Tucson, said having an oral option to treat obstructive sleep apnea would be "game-changing."

"As a reminder, to treat sleep apnea right now, we have instruments that work really well, but they can be complicated and difficult to use," Grandner said. "Not only is it undertreated, but among those who are treated, use is relatively low. This might help get people toward the treatment that they need."

The results of the ATTAIN-OSA trials were published simultaneously in JAMA.

Orforglipron is a small-molecule, non-peptide oral GLP-1 receptor agonist that has already received FDA approval for weight management.

In an editorial accompanying the publication, Diego Mazzotti, PhD, and Damien Stevens, MD, both of the University of Kansas Medical Center in Kansas City, pointed out that for patients with severe disease, "it is expected that orforglipron will be one component of a broader treatment plan."

They suggested that pragmatic trials comparing and combining orforglipron with PAP, oral appliances, tirzepatide (Mounjaro, Zepbound), or other treatments are needed. "For many years, individuals with OSA had few alternatives when PAP was inadequate," they wrote. "Orforglipron adds an oral option to a growing number of treatments from which clinicians and patients can select and work together to build better individualized care."

AHA discussant for the presentation, Ildiko Lingvay, MD, MPH, of the University of Texas Southwestern Medical Center in Dallas, compared the results for orforglipron to those reported for another GLP-1 drug, tirzepatide, which is already approved for obstructive sleep apnea.

She pointed to apparent advantages for tirzepatide over orforglipron in terms of obstructive sleep apnea disease control, with greater improvement in AHI as well as in hypoxic burden, and in safety measures. Cardiovascular risk reduction is also not yet established with orforglipron, while tirzepatide is already FDA-approved for cardiovascular risk reduction in people with diabetes.

"The biggest benefit of orforglipron is really the fact that it comes in a tablet form, for once-daily administration, while tirzepatide requires a cold chain supply and injections," Lingvay noted. "The take-home message is that orforglipron is the first ever oral therapy to have shown improvements in disordered breathing as well as beneficial effects on cardiovascular risk factors, and that includes weight, systolic blood pressure, and inflammatory markers."

The ATTAIN-OSA program included two 52-week, phase III, multicenter, double-blind, placebo-controlled trials involving patients on PAP (N=349) or not on PAP (N=363). The studies were carried out at 66 sites in the U.S., Argentina, Brazil, China, the Czech Republic, Germany, Japan, Mexico, and Taiwan.

Adults with moderate-to-severe obstructive sleep apnea and a body mass index of 27 or higher were eligible. Participants were randomly assigned to receive either once-daily orforglipron at the maximum tolerated dose, equivalent to a 9-, 14.5-, or 17.2-mg tablet dose, or placebo.

Gastrointestinal events were the most commonly reported adverse events, occurring in 68% of patients on orforglipron versus 37.4% of those on placebo among the trial participants not on PAP, and in 70.6% of those on orforglipron versus 36.6% of those on placebo in the PAP trial.

来源:MedPage Today · medpagetoday.com